Early trial tests re-engineered immune cells against tough blood cancers
NCT ID NCT04155710
Summary
This early-stage study tested a new cell therapy called IOV-2001 for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that had returned or stopped responding to standard drugs. The main goals were to find a safe dose and see if the treatment could shrink the cancer. It involved a small group of 7 patients whose own immune cells were collected, modified, and infused back to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health
Pittsburgh, Pennsylvania, 15224, United States
-
Baptist Cancer Center
Memphis, Tennessee, 38120, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.